The U.S. Department of Justice’s unusual decision to intervene in a False Claims Act lawsuit against a private equity firm as the majority owner of a pharmacy allegedly involved in a fraudulent scheme should grab the attention of general counsel at such firms, a legal expert said.

But it is too early to tell whether the case represents a new health care fraud enforcement trend for the federal government, or is just a one-off based on the circumstances of the alleged conduct, the expert said.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]